X @Bloomberg

Merck KGaA agreed to collaborate with Skyhawk Therapeutics to develop neurological therapies in a deal that could be valued at more than $2 billion as the German company seeks to bolster its drug pipeline https://t.co/vLn7wSYzqO ...